Author: Duprez, Daniel A

Source: Aging Health, Volume 5, Number 3, June 2009 , pp. 269-279(11)

Publisher: Future Medicine

Abstract:

Blockade of the renin--angiotensin--aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors or Ang II-receptor blockers has been demonstrated to lower blood pressure and to be effective in heart failure and postmyocardial infarction. It is also beneficial in renal disease. These RAAS blockers further activate the RAAS, leading to an increase of plasma renin activity and plasma renin concentration. Aliskiren, the first orally active direct renin inhibitor, is an effective and well-tolerated antihypertensive agent when used as monotherapy or in combination with other antihypertensive agents in patients with mild-to-moderate hypertension. In contrast with angiotensin-converting enzyme inhibitors and Ang II-receptor blockers, aliskiren reduces plasma renin activity. A number of clinical trials with aliskiren are ongoing or completed and provide us with objective evidence regarding the clinical importance of direct renin inhibition in the treatment of cardiovascular disease.

Keywords: aliskiren; diabetes; diabetic nephropathy; direct renin inhibitor; heart failure; hypertension; renin--angiotensin--aldosterone system

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.2217/ahe.09.21

Affiliations: 1: ††Cardiovascular Division, Medical School, University of Minnesota, VCRC -- Room 270, 420 Delaware St SE, MMC 508, Minneapolis, MN 55455, USA., Email: dupre007@umn.edu

Publication date: 2009-06-01

More about this publication?

• Aging Health leading coverage of current and emerging topics relating to the safe and effective management of therapy in the elderly, all subject to rigorous peer review. The journal focuses on the most important advances and highlights their relevance in the clinical setting. The journal has been designed to deliver essential concise information in an easily assimilable format - vital for the increasingly time-constrained professional.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• E-Access Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General) ,  Nursing
• By this author: Duprez, Daniel A

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers